Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
ESC 23: OCEAN(a)-DOSE Trial Update
Author(s): Michelle O'Donoghue Added: 1 year ago
ESC 23 — Dr Michelle O'Donoghue (Brigham and Women's Hospital, US) outlines a trial update from OCEAN(a)-Dose Extension trial (NCT05581303) in this succinct interview. OCEAN(a)-DOSE (Amgen) was a dose-finding study aiming to evaluate a siRNA, olpasiran, and its effect on risk for coronary heart disease death, myocardial infarction or urgent coronary revascularization when administered… View more

Prevention & Chronic Conditions
ACC 25 Late-Breaking Discussion: The API-Cat Study
Author(s): Harriette Van Spall , Isabelle Mahé Added: 1 month ago
ACC 25 - The API-CAT Study shows reduced-dose apixaban is non-inferior to full-dose apixaban for extended anticoagulation in patients with active cancer who have completed 6 months of anticoagulant therapy for venous thromboembolism (VTE).Late-Breaker host, Dr Harriette Van Spall (McMaster University, Hamilton, CA) is joined by Prof Isabelle Mahe (Paris Cite University, Paris, FR) to discuss the… View more

Anticoagulation

Vascular Disease and Surgery
Dual-pathway Inhibition versus Aspirin Monotherapy
Author(s): Dirk Sibbing , Michael J Blaha , Rajinder Chawla , et al Added: 1 year ago

Anticoagulation

Prevention & Chronic Conditions
Research Area(s) / Expertise: Job title: Head of the Computed Tomography (CT) Unit
ESC HF 25: The VELOCITY Study
Author(s): Stephen J Greene Added: 2 days ago
ESC HF 25 - VELOCITY shows bypassing an initiation dose of 2.5mg, and and beginning with 5mg vericiguat safe and tolerable in 9/10 patients with heart failure with ejection fraction <45%.Prof Stephen Greene (Duke Clinical Research Institute, US) discusses the findings from VELOCITY (NCT06195930; Bayer), a phase 2b open-label clinical study evaluating the tolerability and safety of an… View more

Heart Failure
EP 113: Your Guide to Radiation Hygiene: Insights from Manufacturer and Users
Added: 11 months ago
This week on Parallax, Dr Ankur Kalra welcomes Eric Radtke, Vice President at Worldwide Innovations & Technologies, Inc, and Barbara Breininger, a cardiovascular radiologic technologist and clinical manager with 26 years of experience.This special episode dives deep into the crucial topic of radiation hygiene, exploring it from the perspectives of both manufacturers and users of radiation safety… View more

Guidelines & Statements

Electrophysiology & Arrhythmia
ESC HF 25: The TITRATE-HF Study
Author(s): Jasper J Brugts Added: 2 days ago
ESC HF 25 - TITRATE-HF shows 65% of patients with de novo heart failure receive guideline recommended medical therapy at 6 months in the Netherlands.Dr Jasper Brugts (Erasmus University Medical Centre, NL) joins us to discuss the outcomes from the TITRATE-HF study, which investigated adherence to the 2021 ESC guideline reccommendations for patients with heart failure with reduced ejecton fraction… View more

Guidelines & Statements

Heart Failure
ACC 2025: The ALPACA Phase 2 Trial
Author(s): Steven E Nissen Added: 1 month ago
ACC 2025 - 540-day follow up of lepodisiran in patients with elevated lipoprotein(a) (Lp(A)) shows the extended duration of action of lepodisiran will allow infrequent dosing in the ongoing cardiovascular outcome trial.Dr Steven Nissen (Cleveland Clinic, Cleveland, US) joins us onsite at ACC to discuss the ALPACA phase 2 trial (NCT05565742), investigating the safety and efficacy of lepodisiran,… View more

Prevention & Chronic Conditions
Author(s): Apisara Lohachatinante , Nuttanun Kittikunkanyakit , Sayamon Sukkha , et al Added: 9 months ago

Anticoagulation